Post-mortem human studies have investigated the amount of C3 in the brain of individuals with AD and found 60% of GFAP-positive astrocytes in the pre-frontal cortex of individuals with AD were expressing C3 as well (Liddelow et al. 2017). This evidence concerns the gene GFAP and Alzheimer disease.